We publish EVERYTHING sent to

Catalent to Acquire Paragon for $1.2B, Sharp Wins MHRA Approval for Clinical Services CoE, and More in Today’s CP Direct


Catalent to Acquire Paragon for $1.2B, Sharp Wins MHRA Approval for Clinical Services CoE, and More in Today’s CP Direct
 Trouble viewing this email? Read it online
Follow us on:       
Sponsored by Metrics
April 17, 2019
Magazine  I  News  I  Research  I  Directory  I  Topics  I  Classifieds  I  Resources  I  Provider Microsites
Sponsored by Jubilant HollisterStier


Video: Driving Trends Within Commercial & Clinical Mfg.
Robert Lee of Particle Sciences discusses emerging trends along with how to keep up
Watch Here >>

Video: Vertex Takes a Risk-based Approach to UAT
Re-engineering processes with a modern EDC technology
Watch Here >>

High Pressure Silicone Tubing
Increase flow rates and reduce processing time with AdvantaPure®’s unreinforced silicone tubing for high pressure applications. Called APHP, it offers working pressures that are triple those of standard silicone transfer tubing, as well as full vacuum on all six stocked sizes. It’s flexible, translucent, durable, and ideal for Single-Use. Case study available. Made in USA.
Learn More >>


Catalent to Acquire Paragon for $1.2B
To provide new expertise and capabilities in fast-growing gene therapy space

Sharp Gets MHRA Approval for Clinical Services CoE
Can now offer a range of clinical and commercial services from the $12 million facility

Process Understanding Central to Successful Drug Synthesis
James Springer and Robert Hughes – senior R&D staff from Albemarle FCS – discuss how a high level of process understanding is required with today’s complex APIs to achieve the necessary robust, high-yielding and cost-effective synthetic routes.

Hovione Acquires Rights For Inhaler Device
Affordable, multi-use blister-based dry powder inhaler will be marketed as the Papillon DPI

Almac Expands Global Analytical Services Capability
To bolster operations at its Athlone facility

New Liver Tissue Microarrays Available – What Would Benefit Your Research?
SEKISUI XenoTech offers an increasing variety of tissue microarrays for liver disease research, and has conducted studies utilizing a newly available pediatric array…

WuXi Biologics, I-Mab Biopharma Ink Long-term Strategic Pact
WuXi to provide CMC development and commercial manufacturing

April 2019

Latest Issue Check out the feature
from the latest issue.




Colbert’s Clean Carton Passes the Test
Released by: Colbert Packaging
One Clean Carton™ has been introduced to provide access to packaging that meets the highest standards for sustainable, pharmaceutical and food-safe packaging.

Microsite Spotlight

Jubilant HollisterStier Contract Manufacturing & Services
Jubilant HollisterStier Contract Manufacturing & Services is an integrated contract manufacturer of sterile injectables, ophthalmics, otics and sterile and non-sterile topicals and liquids.


Need a job? Need to fill a job? There’s a lot of interest in’s Job Bank
Find out about new employment opportunities and visit‘s Job Bank today! To find out how to add a job, contact Gary Durr, or Damaris Kope,

We hope you enjoyed this edition of Contract Pharma Direct’s Newsletter

You are receiving this message because you opted in at To change your preferences or unsubscribe please use the links below.

To ensure delivery and proper display of your emails, please add our email address ( to your address book and if needed enable images in your email client.

To update your user profile please click here.

To unsubscribe or change your email subscription preferences please click here.

If you are having trouble with receiving Contract Pharma Magazine or would like to receive it, click here.

Advertise with us

Our mailing address is:

Contract Pharma
Rodman Media
25 Philips Parkway, Montvale, NJ 07645 USA
Tel: 201-825-2552, Fax: 201-825-0553

© Copyright 2019 Contract Pharma All rights reserved.


seo uk says:

Parasite backlink SEO works well 🙂

Like!! Really appreciate you sharing this blog post.Really thank you! Keep writing.

Leave a Reply